Business Wire

STAR EnviroTech Wins Federal Patent Appeal From Competitor Redline Detection

8.2.2016 08:07 | Business Wire

Del

Global Diagnostic Smoke® Technology leader STAR EnviroTech, Inc. has won the final U.S. patent challenge by competitor Redline Detection, LLC, in the US Federal Circuit Court of Appeals. In a precedential 33-page opinion1, the Court fully upheld STAR's "nitrogen smoke" patent. This technology is used by every major automaker (OEM).

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160208005300/en/

STAR EnviroTech, Inc. has won the final U.S. patent challenge by competitor Redline Detection, LLC.  ...

STAR EnviroTech, Inc. has won the final U.S. patent challenge by competitor Redline Detection, LLC. as the US Federal Circuit Court of Appeals has fully upheld STAR's "nitrogen smoke" patent. STAR EnviroTech's Diagnostic Smoke(R) automotive leak detection technology is approved/mandated by every major automaker (OEM) and used by leading automotive aftermarket equipment makers worldwide. (Photo: Business Wire)

Previously, STAR prevailed against three other Redline Detection attempts to take STAR’s “nitrogen smoke” technologies for safer EVAP testing: two patent re-examination proceedings and an Inter Partes proceeding before a three-judge panel of the U.S. Patent Trial and Appeal Board (PTAB).2 Two other failed Redline Detection attempts attacked two of STAR’s dye patents. STAR makes these safe, industry-standard technologies available to leading tool manufacturers serving every major automaker and the automotive aftermarket. Twenty other STAR patents were unchallenged by Redline Detection.

"This Appellate Court victory, coming on the heels of our five prior patent challenge wins, reaffirms that neither Redline nor its customers can use our patented 'nitrogen smoke', or our 'smoke dye' technologies”, said STAR EnviroTech CEO Jim Saffie. “We’ve worked hard to secure our U.S. and international patents. We invented this technology and we have an ethical obligation to our distribution partners to guard those patents. They’ve made an investment in us and our technologies. We will protect those investments.”

STAR EnviroTech, the inventor of Diagnostic Smoke® Leak Detection Technologies, worked in collaboration with various partners including Ford, GM and Chrysler, through the OEMs’ USCAR organization, to develop a universally-accepted vehicle fuel evaporative (EVAP) and vacuum system leak detection technology. Today, STAR Technologies are OEM-mandated worldwide, available in more than 125 countries and more have been sold by leading tool manufacturers and distributors than all competitors’ products combined.

STAR’s “nitrogen smoke” patent (6,526,808) uses an exclusive method of producing smoke with any inert gas to virtually eliminate the risk of a vehicle fuel tank fire or explosion during an EVAP test. Papers published by SAE International3 and other empirical data support this method as safer than testing with shop air in a fuel tank. Adding air containing oxygen to a volatile environment such as a fuel tank can create a flammable mixture inside the fuel tank, but “nitrogen smoke” eliminates the risk of fire during the testing process.

STAR’s “smoke dye” patents use a unique, non-contaminating, non-permanent UV dye to mark the spot of the leak(s), making even hidden leaks easy to find.

Headquartered in Huntington Beach, California, STAR EnviroTech, a privately-held corporation, develops award-winning, industry-standard technologies for leak testing in fuel evaporative (EVAP), vacuum/induction, turbo, and other vehicle and non-vehicle systems.

STAR technologies are inside smoke machines from the leading tool manufacturers supplying the automotive, truck, industrial, marine, and aviation industries, including the Canadian Air Force and the U.S. Military.

For more information on STAR EnviroTech, go to: http://www.StarEnviroTech.com

See also: http://knobbe.com/news/2016/01/knobbe-martens-client-star-envirotech-wins-affirmance-ipr-decision-finding-patent-valid

1 Redline Detection, LLC V. STAR EnviroTech, Inc. [opinion] Appeal Number: 15-1047.
2 (USPTO Reexams: 90/011,916, 90/011,544, 90/011,545, 90/009,683 and Case: IPR2013-00106)
3 SAE International Papers:

- Fuel Tank and Charcoal Canister Fire Hazards during EVAP System Leak Testing
- Oxygenated Fuel Considerations for In-Shop Fuel System Leak Testing Hazards

Contact information

PRNewsBureau
Phil Sasso, +1 847-250-7445
phil@prnewsbureau.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

IFF to Present at the Barclays Global Consumer Staples Conference21.8.2017 20:15Pressemelding

Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF), a leading innovator of sensory experiences that move the world, today announced that Andreas Fibig, Chairman and Chief Executive Officer will present at the Barclays Global Consumer Staples Conference in Boston, MA on Thursday, September 7, 2017 at 11:15 a.m. EDT. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for explorati

Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform21.8.2017 20:11Pressemelding

Celularity, Inc., a newly formed biotechnology company, today announced its acceleration of cell and tissue regenerative therapies to address unmet medical needs in cancer and chronic and degenerative disease. Celularity completed their Series A financing with contributions from several biopharma companies, including Sorrento Therapeutics, United Therapeutics Corporation and Human Longevity, Inc., and entrepreneurial investors. Celularity has been created through the contributions of extensive intellectual property, clinical-stage assets, basic and clinical research, and development expertise including: Several clinical-stage immuno-oncology and regenerative medicine assets and a pipeline of pre-clinical assets Proprietary allogeneic (“readily accessible”) immunotherapy platform 200+ issued and pending patents in cell therapy

European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 13:25Pressemelding

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the

IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 12:00Pressemelding

IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman

PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 08:03Pressemelding

PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate

Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 08:00Pressemelding

Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom